Abridge provides an enterprise‑grade generative AI platform that listens to patient‑clinician conversations and creates real‑time, context‑aware clinical notes directly within Epic’s workflow. The system leverages prior encounter data, health‑system guidelines, and billing code alignment to produce compliant, billable documentation across specialties and languages, reducing clinician workload and closing revenue‑cycle gaps.

The startup develops an integrated population health analytics platform that utilizes data-driven insights to enhance telemedicine services for vulnerable senior populations. This platform enables health plans and provider organizations to effectively manage healthcare costs and risks by coordinating clinical and social services.

Astrata provides AI-powered HEDIS software that utilizes natural language processing and FHIR/CQL standards for efficient chart abstraction and data management. The platform enhances health plans' quality ratings by enabling year-round prospective HEDIS reviews and improving population health insights through advanced data analytics.

The startup develops gene therapy solutions for retinal diseases and rare ophthalmic conditions using proprietary AAV vectors for targeted, cell-type specific delivery. Their toolkit enables healthcare professionals to administer gene treatments through a minimally invasive intravitreal approach, allowing for reduced dosages and improved patient outcomes.

The startup provides personalized T-cell therapy that utilizes the unique specificity of each patient's T-cells to target the molecular profile of their cancer. This approach enables healthcare providers to deliver tailored and rapid treatments for various cancer types, improving patient outcomes through individualized therapy.

BrainCheck offers a mobile interactive platform for cognitive health assessment, utilizing FDA Class II medical device technology to conduct rapid screenings and detailed evaluations of cognitive function. This solution enables healthcare providers to identify cognitive impairments early, facilitating timely intervention and personalized care planning for patients at risk of conditions like dementia and Alzheimer’s.

Butterfly Network provides a portable, integrated point-of-care ultrasound (POCUS) ecosystem powered by its Ultrasound-on-Chip™ technology. This solution makes high-quality ultrasound imaging accessible to clinicians for real-time patient assessment and diagnosis across diverse medical specialties and care settings.

Carta Healthcare combines artificial intelligence with expert clinical data abstractors to enhance the speed and quality of clinical data abstraction for healthcare registries. This approach addresses the inefficiencies of traditional data abstraction methods, which are often time-consuming, labor-intensive, and costly, by delivering high-quality data more efficiently.

Cerevance utilizes its proprietary Nuclear Enriched Transcript Sort sequencing (NETSseq) platform to identify novel therapeutic targets for neurological diseases, including Parkinson's and Alzheimer's. The company develops cell type-specific therapies aimed at addressing the unmet medical needs associated with neurodegenerative and psychiatric disorders.

Code Biotherapeutics is developing a multivalent synthetic DNA delivery platform, 3DNA®, to enhance the precision and bioavailability of non-viral gene therapies for life-threatening diseases. The company focuses on overcoming challenges such as dose-related toxicity and off-target effects, with a primary research emphasis on Duchenne Muscular Dystrophy.

Elektra Health offers a telemedicine platform that connects women experiencing menopause with board‑certified clinicians and dedicated health coaches for virtual appointments, prescriptions, labs, and personalized wellness plans. The service also provides an evidence‑based education library and a private, moderated community for peer support and expert‑led events, enabling comprehensive, continuous care without in‑person visits.

Generian Pharmaceuticals utilizes a proprietary drug discovery platform to identify orally bioavailable small molecules that modulate protein stability through activation, stabilization, or degradation. This approach targets diseases with high unmet needs, particularly those currently treated with biologics, enhancing patient access and reducing treatment costs.

The platform provides integrated resources for multi-modal specialty care, including behavioral health support and a longitudinal care team. This approach enhances visibility and trust for healthcare providers, addressing the need for coordinated patient management and comprehensive care delivery.

Globin Solutions, Inc. develops heme-based antidotal therapies to treat human poisonings by utilizing globin chemistry and protein engineering techniques. Their focus is on creating effective treatments that can rapidly neutralize toxins, addressing a critical need in emergency medical care.

The startup operates a healthcare venture studio that utilizes blockchain and distributed ledger technologies to create new business models for healthcare challenges. By partnering with healthcare and life sciences enterprises, it facilitates the exchange of professional credentials and peer supply, enhancing collaboration and efficiency in addressing issues like data integrity and interoperability.

Infectious Disease Connect provides telemedicine and decision‑support software that links hospitals with board‑certified infectious disease specialists, antimicrobial stewardship experts, and infection‑prevention teams. By delivering real‑time, evidence‑based therapy guidance and virtual stewardship alerts through its ILÚM Insight® platform, the service reduces patient transfers, shortens lengths of stay, and lowers antibiotic use, helping health systems improve outcomes and control costs.

Koda offers a video-based platform that facilitates advance care planning and chronic kidney disease management through interactive, data-driven tools and clinical support. This solution addresses the challenge of unplanned medical decisions by helping patients create actionable directives that ensure their healthcare wishes are clearly communicated and understood.

Latigo is a clinical-stage company developing non-opioid pain medications that target pain at its source, aiming to provide effective and rapid relief without the risk of addiction. The company addresses the significant unmet need for new pain therapies, as current treatments often lead to dependency and have remained unchanged for decades.

The startup has developed a medical information-sharing platform that utilizes encrypted, single-use, peer-to-peer communication channels to connect disparate health data silos. This decentralized architecture enhances patient privacy by eliminating cloud storage of health data, enabling secure information exchange between patients and health systems.

Moxe provides an EHR‑neutral, API‑first interoperability platform that automates the secure exchange of clinical data between providers and payers. The service encrypts data, normalizes it into standardized formats for use cases such as risk adjustment, payment integrity and care management, and offers real‑time dashboards and role‑based portals for monitoring and analytics.

Mozart Therapeutics is developing first-in-class CD8 Treg modulators to restore immune homeostasis in patients with autoimmune diseases by targeting immune surveillance dysregulation. Their therapies aim to prevent progressive inflammation and tissue damage associated with pathogenic autoimmune responses.

Noema Pharma is a clinical-stage biotech company developing disease-modifying therapeutics for central nervous system conditions, including persistent seizures, severe pain, and involuntary tics. Their therapies aim to improve the quality of life for patients with both rare and common neurological disorders by targeting the underlying symptoms rather than merely managing them.

Novasenta develops immunotherapy treatments that leverage the interaction between cancer and the immune system to target and eliminate tumor cells. This approach aims to improve patient outcomes by enhancing the body’s natural defenses against cancer.

Optain Health provides an integrated teleophthalmology screening platform utilizing an FDA-cleared robotic camera for rapid, undilated imaging at the point of care. This system allows any staff member to capture images for specialist grading of conditions like diabetic retinopathy, streamlining workflow and improving patient adherence. The platform securely integrates with existing EHR systems to deliver actionable, ICD-10-coded reports directly into clinical dashboards.